Posters and Presentations

  • 2017 - 2015
  • 2014 - 2010
  • 2009 - 2005
  • 2004 - 2000
  • Older
  • View All
  • D. Kappeler, I. Heimbeck, P. Bruijnzeel, E. Chevalier, A. Wach, J. Zimmermann, P. Barth

    POL6014, ein hochpotenter inhalativer Inhibitor der humanen Neutrophilen Elastase mit vielversprechenden ersten Studienergebnissen in Mukoviszidose-Patienten | 20th Annual Meeting Muko e.V. - Nov 16 - 18, 2017 - Würzburg

  • Patrick McManus, Eva Borowski, Wolfgang Timmer

    Conducting global studies with a flexible network of specialized CROs: How can we achieve Process Standardization & Remain Flexible to achieve Milestones? | Canada Talks Pharma 2016 - May 27, 2016

  • U. Homburg, H. Renz, W. Timmer, J. Hohlfeld, F. Seitz, K. Lüer, A. Mayer, A. Wacker, O. Schmidt, J. Kuhlmann, A. Turowska, J. Roller, K. Kutz, G. Schlüter, N. Krug, H. Garn

    Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma. Letter to the Editor. | Journal of Allergy and Clinical Immunology (JACI). Published Online: April 01, 2015.

  • W. Timmer

    Most common clinical pharmacology trials: FIM, safety, exploratory PK and PD, PoC trials, drug-drug-interaction, drug-food interaction, bioavailability, bioequivalence, QTc trial, adaptive designs, basic concepts of clinical development planning | Lecture at the Introductory Course in Translational Medicine / Applied Human Pharmacology – Part I Arbeitsgemeinschaft für angewandte Humanpharmakologie [Association for Applied Human Pharmacology] (AGAH e.V.), Feb 18, 2015, Frankfurt

  • W. Timmer

    Design elements of human pharmacology trials | Lecture at the Introductory Course in Translational Medicine / Applied Human Pharmacology – Part I Arbeitsgemeinschaft für angewandte Humanpharmakologie [Association for Applied Human Pharmacology] (AGAH e.V.), Feb 17, 2015, Frankfurt

顶级少妇